Generex Biotechnology Announces That FDA has Accepted the Pre-IND Briefing Package for the Company’s Ii-Key-SARS-CoV-2 Vaccine and Will Provide a Written Response by August 24, 2020

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs